Neostem (AMEX:NBS.U)
Historical Stock Chart
From May 2019 to May 2024
NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the
collection, processing and long term storage of stem cells from healthy
adults for personal use in times of critical medical need, today
announces its common stock and units have been approved to be listed on
the American Stock Exchange under the ticker symbols—NBS
and NBS.U—and will start trading August 9,
2007. The listing followed the completion of a public-offering in excess
of $5 million and a one-for-ten reverse stock split.
The listing on the American Stock Exchange is consistent with the Company’s
strategic mission to attract institutional investors and to provide
long-term value for its shareholders.
“We are extremely proud of our recent
achievements and of surpassing yet another milestone for the benefit of
our shareholders,” said Robin Smith, M.D.,
Chairman and Chief Executive Officer of NeoStem. “It
is an honor to be listed on the American Stock Exchange and to enjoy all
the benefits of its long and storied history. We believe these recent
developments will be major catalysts as we move forward into a position
of leadership in the burgeoning market for stem cell therapies and
services.”
The closing of this offering is the latest validation of NeoStem’s
high-growth business model focused on developing next generation
services and therapies that have the potential to help millions of
health-conscious individuals. The total offering comprises units at a
price of $5 per unit. Each unit consists of one share of common stock
and one-half a Class A warrant to purchase one-half a share of common
stock. Thus, 1,000 units consist of 1,000 shares and warrants to
purchase 500 shares of common stock.
The Underwriter for the offering was Mercer Capital Ltd., members of the
National Association of Securities Dealers, Inc.
NeoStem’s common stock, units and Class A
warrants have been accepted for listing on the American Stock Exchange
under the symbols “NBS”,
“NBS.U”, and “NBS.WS”
respectively, effective upon consummation of the initial closing of the
offering. The CUSIP for the Common Stock is 640650305, the CUSIP for the
Units is 640650206, and the CUSIP for the Warrants is 640650115.
NeoStem’s first-to-market competitive
advantage uniquely positions the Company to capitalize on the hundreds
of adult stem cell-based therapy clinical trials currently underway. As
these stem cell-based therapies become available, NeoStem clients will
be among the first to benefit from the life saving progress that has
already been made for such debilitating conditions as cancer, heart
disease, multiple sclerosis, lupus, and many others.
About NeoStem, Inc.
NeoStem is a biotechnology services company enhancing the delivery of
adult stem cell therapeutics to health-conscious consumers. The Company
is developing a nationwide network of adult stem cell collection
centers, enabling people to donate and store their own stem cells with
NeoStem for personal use years or decades later in times of critical
medical need.
The proprietary NeoStem technologies empower health-conscious consumers
to help protect their future health by undergoing treatment with their
own stem-cells - providing an accessible supply of healthy, genetically
matched stem cells for use in the eventuality of illness.
Currently underway are hundreds of stem cell-based research programs and
clinical trials investigating the use of these non-controversial adult
stem cells, such as those collected from donors under NeoStem's methods.
As the nation's population ages and encounters serious age-related and
congenital health issues, NeoStem has positioned itself as a leader in
the fast-growing national trend toward personal "bio-insurance."
The Company's non-capital intensive business plan is a service model
that is completely scalable, thus minimizing risk levels ordinarily
related to most long-term biopharmaceutical research and development.
Under its strategic business plan, NeoStem has begun opening a
nationwide network of adult stem cell collection facilities. Its stem
cell collection systems will be located in existing physician offices
and medical facilities, where the procedures and care can be
administered by trusted personal doctors and medical professionals.
For more information, please visit: www.neostem.com.
For other information and resources about the Company, visit www.CFSG1.com
or www.trilogy-capital.com/tcp/neostem/quote.html.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements concerning the ability of
NeoStem, Inc. ("the Company") to develop the adult stem cell business,
the future of regenerative medicine and the role of adult stem cells in
that future, the future use of adult stem cells as a treatment option
and the potential revenue growth of the Company's business. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements.
The Company's ability to enter the adult stem cell arena and future
operating results are dependent upon many factors, including but not
limited to (i) the Company's ability to obtain sufficient capital or a
strategic business arrangement to fund its expansion plans; (ii) the
Company's ability to build the management and human resources and
infrastructure necessary to support the growth of its business; (iii)
competitive factors and developments beyond the Company's control; (iv)
scientific and medical developments beyond the Company's control; (v)
the Company's inability to obtain appropriate state licenses or any
other adverse effect or limitations caused by government regulation of
the business; and (vi) other risk factors discussed in the Company's
periodic filings with the Securities and Exchange Commission which are
available for review at www.sec.gov
under "Search for Company Filings."
Pursuant to an October 1, 2006 agreement, Consulting For Strategic
Growth I, Ltd. ("CFSG1") provides the Company with consulting, business
advisory, investor relations, public relations and corporate development
services, for which CFSG1 receives a fixed monthly fee for the duration
of the agreement and received shares of NeoStem's common stock.
Independent of CFSG1's receipt of cash or other compensation from the
Company, CFSG1 may choose to purchase the common stock of the Company
and thereafter sell those shares at any time it deems appropriate to do
so. For more information, please visit www.cfsg1.com.